Battlefield Pain Management � Analgesic
Dept of Defense · DEFENSE HEALTH AGENCY (DHA)
Opportunity details
Battlefield Pain Management � Analgesic is currently listed as accepting responses on SAM.gov. Buyer context: Dept of Defense · DEFENSE HEALTH AGENCY (DHA). Industry classification: Research and Development in Biotechnology (except Nanobiotechnology) (NAICS 541714). Product/service classification: HEALTH R&D SERVICES; HEALTH CARE SERVICES; EXPERIMENTAL DEVELOPMENT (PSC AN13). Set-aside: No Set aside used. Performance location: Frederick, MD, USA. Notice type: Solicitation. GovGazette adds public award history and related pages to help you decide whether to keep reading. Check all requirements on SAM.gov.
- Check the NAICS and PSC codes, set-aside rules, place of performance, and time left before the deadline.
- This notice lists a set-aside (No Set aside used). Confirm your certification and size status under the official SBA and agency rules before you spend time on a proposal.
- This page uses 96 related public awards. The range describes past awards; it does not set a bid price.
- Use the NAICS and PSC pages to find other open notices under the same codes.
- Response deadline
- Aug 14, 2026, 12:00 PM EDT
- Set-aside
- No Set aside used
- Place of performance
- Frederick, MD, USA
- Posted
- Jul 23, 2026
- Solicitation
- HT942726RE009
- Contracting office
- DEFENSE HEALTH AGENCY · FORT DETRICK · MD
- Source
- SAM.gov
Description
This Request for Prototype Proposal (RPP) is being issued under the authority of prototype Other Transaction Authority (pOTA) 10 U.S.C. 4022 by the Defense Health Agency Contracting Activity (DHACA), in support of the Defense Health Agency, Portfolio Acquisition Executive Medical Products (PAE MP), Warfighter Protection and Acute Care Project Management Office (WPAC PMO) located in Frederick, Maryland, at Fort Detrick. The requirement is for Analgesic Product for Battlefield Use. Please see the attached RPP and attachments for additional information. Amendment 0001 The purpose of Amendment 0001 is to: 1. Amend the Request for Prototype Proposal (RPP) as follows: - Extend the proposal due date from 30 July 2026 to 14 August 2026 (RPP Amendment 0001, page 1 and page 17). No additional questions/phone calls regarding the RPP will be accepted. - Update the word �drug� to �product� to align with the language (RPP Amendment 0001, page 2, section 1.1, third paragraph) - Clarify language regarding the Spend Plan (RPP Amendment 0001, page 13, section 3.5 Volume III: Administrative and Cost Volume, Attachment E � Cost Sheet Template with priced milestones, first paragraph). - Add additional Vendor requirements (RPP Amendment 0001, page 15, section 3.5 Volume III: Administrative and Cost Volume, Other Administrative Requirements). 2. Amend the RPP, Attachment A � Statement of Objectives (SOO) as follows: - Update the Revised Date (page 1). - Update language throughout to clarify the Government�s intent regarding drug versus product. - page 1, section 1. Purpose/Objective, second and third paragraphs - page 2, section 4 Objectives, second, third and fifth paragraphs - page 3, section 4 Objectives, first paragraph - page 5, Desirable prototype characteristics and performance, first paragraph - Revise the following Desirable prototype characteristics and performance: (2), (6), (9), and (13) (page 5 and page 6). - Revise the following Deliverables: Deliverable 3 and Deliverable 12 (page 7 and page 9, respectively). 3. Answer questions received from potential performers (see RPP Amendment 0001, Attachment 1). There are no other changes.
What similar awards have paid
See what agencies paid for similar work. This public history does not set a bid price, estimate a cost, or predict an award.
Typical award size
$4.36M
Middle of the pack for similar past awards
Most similar awards fall between $741,824 and $20.00M
Who has won work like this
These firms won similar public awards. Use the list for competitor research or teaming, not as a ranking.
- 1AMGEN USA INC2 awards$714.70M
- 2SIGA TECHNOLOGIES, INC.1 award$624.44M
- 3EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC.1 award$118.56M
- 4MAPP BIOPHARMACEUTICAL, INC.1 award$110.88M
- 5MODEX THERAPEUTICS, INC1 award$110.05M
- 6VENATORX PHARMACEUTICALS INC1 award$107.19M
- 7CROSSJECT SA1 award$104.15M
- 8LOCUS BIOSCIENCES INC1 award$73.89M
Drawn from official USAspending contract records. Always confirm requirements on the SAM.gov notice before you bid.
For research only. This is not legal advice or a promise of an award. Always verify requirements on the official SAM.gov notice. Past award amounts are public history, not a suggested bid or prediction. Open the original SAM.gov notice for the official record.